Clifford Chance

Clifford Chance advises Lepu Biopharma on its Hong Kong IPO and Listing

Leading international law firm Clifford Chance has advised Lepu Biopharma Co., Ltd. on its approximately US$116.1 million initial public offering (IPO) and listing on the mainboard of the Hong Kong Stock Exchange under Chapter 18A of the Listing Rules. The Joint Sponsors are CICC and Morgan Stanley. Lepu Biopharma's product pipeline features broad-spectrum anti-tumour drugs, including primarily the anti-PD-1 antibody candidate, as the backbone, and a dual focus on ADC and oncolytic virus drug candidates, maximizing synergies in both drug efficacy and commercialisation.

Partners Fang Liu and Tianning Xiang co-led the deal, with support from a team in Beijing and Shanghai including counsel Samson Chan, senior associate Erxin Lu, associates Ada Zheng, Liying Liang and trainee Ruonan Tang.

Fang Liu commented, "We are honoured to assist Lepu Biopharma in achieving this milestone, which is also the first Chapter 18A IPO and listing in Hong Kong this year. This further demonstrates our exceptional track record and market-leading expertise in the innovative biotech sector."

Clifford Chance's Greater China IPO practice regularly advises on the IPOs of the most innovative biotech, pharmaceutical and healthcare companies, including Sirnaomics, MicroTech Medical, Zylox-Tonbridge Medical Technology, Harbour BioMed and Ascentage Pharma.